Apollomics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a APLM research report →
Price Chart
About the company
Apollomics, Inc. , a biotechnology enterprise established in 2015 and headquartered in Foster City, California, conducts its research and development operations across California, Hangzhou, Shanghai, China, and Australia. The company is dedicated to discovering and advancing innovative oncology treatments to address critical unmet medical requirements.
- CEO
- Hung-Wen Chen
- IPO
- 2021
- Employees
- 14
- HQ
- Foster City, CA, US
Get TickerSpark's AI analysis on APLM
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $45.28M
- P/E
- -64.77
- PEG
- -0.27
- P/S
- 0.00
- P/B
- -3.38
- EV/EBITDA
- -8.92
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 103.09%
- ROIC
- 105.41%
Latest fiscal year · YoY change
- Revenue
- $8.50M+4192.9%
- Gross Profit
- $8.24M+4064.1%
- Op Income
- $-9,473,000
- Net Income
- $-10,939,000+79.7%
- EPS
- $-7.57+85.7%
- OCF Growth
- +63.9%
- FCF Growth
- +64.0%
- 52W High
- $28.29
- 52W Low
- $12.58
- 50D MA
- $21.14
- 200D MA
- $18.87
- Beta
- 1.56
- RSI (14)
- 30
- Avg Volume
- 11.11K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Apollomics said 2023 was a progress year for vebreltinib and APL-106, with FDA feedback supporting continued enrollment and cash expected to last into the first quarter of 2025.· March 28, 2024
- FDA feedback on vebreltinib was described as informative and encouraging, but the company still needs more patient data for its planned filing paths.
- For MET exon 14 skipping NSCLC, management cited ORR of 66.2% in 71 treatment-naive patients and 61.1% in 36 previously treated patients, with median DORs of 16.5 and 16.7 months.
- For MET amplification NSCLC, Apollomics is continuing enrollment in Sparta to improve precision and geographic diversity; management said an NDA for accelerated approval could potentially come in 2026 if results are positive.
- APL-106’s China bridging study in relapsed/refractory AML was fully enrolled by end-2023, with top-line data expected in the first half of 2025.
- Cash, cash equivalents, bank deposits and money market funds were $37.8 million at year-end 2023, and management said that supports operations through the first quarter of 2025.
For the year ended December 31, 2023, Apollomics reported cash, cash equivalents, bank deposits and money market funds of $37.8 million versus $58.9 million at December 31, 2022. R&D expense was $34.2 million, including $5.9 million of stock-based compensation, versus $35.4 million in 2022; G&A expense was $20.6 million, including $6.8 million of stock-based compensation, versus $9.9 million in 2022. Net loss was $172.6 million, or $2.32 per diluted share, versus a net loss of $240.8 million, or $8.44 per diluted share, in 2022. Net cash used in operating activities was approximately $43.2 million versus $42.8 million in the prior year. Management said current cash is sufficient to fund planned operations through the first quarter of 2025. No quarterly revenue or gross margin figures were reported on the call.
The CEO framed 2023 as a year of “significant accomplishment,” emphasizing progress for vebreltinib and APL-106 and the company’s focus on moving its lead assets toward regulatory approval. He highlighted more than 500 patients treated to date across the SPARTA and KUNPENG programs and said the company is concentrating on three initial vebreltinib indications, while stressing focus on the two lead programs given limited cash. His tone was constructive but disciplined, repeatedly pointing to continued enrollment, FDA dialogue, and a narrow strategic focus.
The new CFO said his near-term focus is helping with the company’s 20-F filing and bringing experience in finance, capital formation, and strategic collaborations from prior small biopharma roles. On the numbers, he said year-end cash and equivalents plus bank deposits and money market funds were $37.8 million, down from $58.9 million a year earlier, and that this is expected to fund operations through Q1 2025. He also broke out 2023 R&D at $34.2 million, G&A at $20.6 million, and net loss at $172.6 million, noting 2023 included $46.0 million of capital-markets-related expenses and that some 2024 costs should be lower after the 2023 de-SPAC and enrollment completion in the APL-106 phase three trial.
Analyst Tim Moore focused on timing for the FDA pathway, asking whether continued enrollment in Sparta would push an NDA into 2026; management said the 12-month follow-up for the current dataset comes up in the summer, but if additional patients are needed the timeline could extend, and they are thinking more in terms of 2025 than 2026. He also asked what the new CFO will contribute and whether 2024 R&D could reach $50 million; management said the CFO will help with filing, capital formation, and collaborations, and declined to give a specific expense guide, instead pointing him to the cash-runway guidance. Management also reiterated that the company is staying focused on vebreltinib and APL-106 because of limited cash.
The bull case is that vebreltinib showed encouraging activity across multiple datasets, including a 66.2% ORR in treatment-naive MET exon 14 skipping NSCLC and durable responses, and FDA feedback did not appear to shut down the program’s regulatory path. Management believes MET amplification NSCLC remains an unmet need and sees a possible accelerated-approval route if additional Sparta enrollment is positive. The company also has another milestone in APL-106 with top-line data expected in the first half of 2025.
The main risks are regulatory and timing-related: management said more patients and more follow-up are still needed, and the timeline for any NDA could slip depending on how much additional data FDA wants. Cash is limited at $37.8 million, and the company is relying on that to bridge to Q1 2025, so execution and spending discipline matter. The company also acknowledged that additional patients in Sparta would extend the timeline, and the GBM program still needs more study data before it can support a US marketing authorization.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 56.6%
- Shares Outstanding
- 2.91M
- Float Shares
- 1.65M
of shares held by institutions
4 13F filers
Buy/sell ratio 1.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Citadel Advisors LLC | 10.66K | ▲ 10.66K |
| Ubs Group AG | 2 | 0 |
| Blackrock, Inc. | 1 | 0 |
| Citigroup Inc | 1 | ▲ 1 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 17, 26 | Huang Ya-Chi | other | 500 |
| Nov 17, 26 | Huang Ya-Chi | other | 500 |
| Sep 15, 26 | Chen Yi-Kuei | other | 5,000 |
| Sep 14, 26 | Chen Yi-Kuei | other | 8,000 |
| Sep 15, 26 | Chen Yi-Kuei | other | 5,000 |
| Sep 15, 26 | LIN PETER KUAN-HOW | other | 10,000 |
| Sep 15, 26 | LIN PETER KUAN-HOW | other | 3,416 |
| Sep 15, 26 | LIN PETER KUAN-HOW | other | 10,000 |
| Sep 14, 26 | LIN PETER KUAN-HOW | other | 6,000 |
| Sep 14, 26 | Yen Hung Hsien | other | 2,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our APLM coverage
Recent articles, reports, and earnings notes.
No research on APLM yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate APLM report →Apollomics Announces $10 Million Private Placement Transaction
globenewswire.com · Aug 11
Apollomics Regains Full Compliance with Nasdaq Listing Requirements
globenewswire.com · Jul 13
Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
globenewswire.com · Jun 24
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
globenewswire.com · Apr 27
Apollomics Inc. Announces $2.0 Million Bridge Financing
globenewswire.com · Apr 1
Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March
defenseworld.net · Mar 28
Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest
defenseworld.net · Mar 18
Apollomics Reports First Half 2025 Financial Results
globenewswire.com · Dec 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.